News Releases
- September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference
- September 10, 2021Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- September 3, 2021Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report®
- August 25, 2021Annovis Bio to Present at Biomarkers for Alzheimer’s Disease Summit 2021
- August 11, 2021Annovis Bio Completes Dosing of Parkinson’s Disease Patients with ANVS401 in Phase 2a Clinical Trial
- July 30, 2021Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
- July 28, 2021Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference
- July 23, 2021Annovis Bio to Present New Data at 2021 Alzheimer’s Association International Conference
- July 20, 2021Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study
- July 2, 2021Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top